Impurities Forum 2019 - Part I - General Strategies for Investigation and Control
Im Auftrag der ECA Academy
Praha, Czech Republic
Seminar Nr. 16955
Unser Seminarservice
Kosten
Dieses Seminar hat leider schon statt gefunden. Wenn Sie aber Interesse an diesem Seminar haben, informieren wir Sie gerne über den neuen Termin oder über weitere Angebote zu dem Thema. Nutzen Sie einfach das folgende Kontaktformular, um uns Ihre Anfrage zu senden.
Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de
Sprecher
DR GERD JILGE, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
Dr Xaver Schratt, GBA Pharma GmbH, Germany
DR ANDREW TEASDALE, AstraZeneca, United Kingdom
DR LISE VANDERKELEN, Nelson Labs, Belgium
Dr Xaver Schratt, GBA Pharma GmbH, Germany
DR ANDREW TEASDALE, AstraZeneca, United Kingdom
DR LISE VANDERKELEN, Nelson Labs, Belgium
Zielsetzung
Part I of the Impurities Forum will provide an opportunity to reinforce and expand your knowledge of the general area of impurities in chemical entities from initial development to the market with emphasis on
- Detection, profiling and control of impurities in drug substances, intermediates and drug products
- Practical aspects of method validation for impurities Determination
- Analytical techniques used for detecting and qualifying impurities
- Extractables and Leachables as a source of impurities
- “Unexpected Impurities” – lessons learned from the Valsartan case
This event is designed to provide a comprehensive review of impurities analysis and characterisation in drug substances and drug products and their recording and reporting.
Hintergrund
Setting specifications for impurities are one of the most critical topics in the development of new drug products. Impurities analysis in drug substances and drug products and their recording and reporting is quite often a challenge for the scientific experts in routine production and quality control.
This challenge is even bigger when profiles of unknown impurities in complex matrices have to be established. The recent Valsartan case made clear the importance of a thorough process understanding.
This challenge is even bigger when profiles of unknown impurities in complex matrices have to be established. The recent Valsartan case made clear the importance of a thorough process understanding.
Zielgruppe
This conference addresses all personnel involved in development of drug substances and drug products from scientific staff to laboratory heads involved in R&D. The needs of Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments will also be covered. This event will also address regulatory requirements and hence is applicable to people working in the regulatory affairs area.
Programm
Impurities analysis and qualification of Impurities in Drug Substances and Drug Products – general overview
- Impurity profiling in synthetic drug substances
- Qualification of impurities
- Degradation studies
- Identification of chiral impurities, polymorphic phases and new impurities
- Residual solvents
- Impurities in starting materials and intermediates
- Pharmacopoeial tests and acceptance criteria
- Drug product specifications and parametric release
Analytical method validation for Impurity determination at various development stages
- Quantification of impurities
- How to define an impurity profile (stress tests)
- Reference substances
- Validation of methods at various development stages
- Statistical approaches to method validation (LOD & LOQ)
Presentation and Workshop:
Analytical techniques for determination and qualification of impurities in Starting Materials and Intermediates
Analytical techniques for determination and qualification of impurities in Starting Materials and Intermediates
- Purity analysis by HPLC, impurity profile
- Residual solvents by GC
- Inorganic impurities (heavy metals, sulphated ash)
- For chiral compounds in addition: enantiomeric purity and proof of the absolute configuration
In the Workshop the participants will learn which activities are necessary to characterize drug substances taking into account the following aspects:
- analytical procedures are necessary for the characterization
- experiments necessary to check the downstream impurities in order to justify acceptance criteria for the respective impurities
- other impurities have to be taken into account
- experiments to be performed in order to get a stability-indicating analytical procedure
Leachables and Extractables
- Why should Extractables & Leachables be assessed?
- Regulatory requirements in the EU and US
- Compendial requirements and industry standards
- Safety qualification of Leachables and Extractables
The subsequent plenary workshop will provide the opportunity to discuss case studies about Leachables and Extractables regarding detection and safety qualification. It will seek, through a practical exercise, to examine the steps involved in a comprehensive E&L evaluation.
Unexpected Impurities: approaches for investigation and determination
- Is there such a thing as ‘unexpected impurities” or is there a lack of process understanding?
- Valsartan – overview of events
- Source of contamination
- Mechanistic understanding
- Examination of risk within other Sartans – overview of how to conduct a risk assessment and to identify key factors
- Are there other Mutagenic Impurities related risks?
GMP Seminare nach Thema
- Qualitätssicherung / Dokumentation
- Regulatory Affairs and Compliance
- Entwicklung / Prüfpräparate
- Datenintegrität
- Qualitätskontrolle / Analytik / Statistik
- GDP - Lager - Logistik
- Computervalidierung
- Validierung / Qualifizierung
- GMP in Produktion / Technik
- GMP für Wirkststoffe und Hilfsstoffe
- Medizinprodukte und Kosmetika
- GMP Basisausbildung
- Packmittel / Verpackung
- Hygiene / Mikrobiologie / Steril
- Biotechnologie
- Einkauf / Betriebswirtschaft / Effizienz
- European Conferences and Education Courses
- Sonstige Themen